Wednesday, March 26, 2008 9:05:00 AM
On a lesser point- Dew has consistently not backed up his statements with facts whether it be IND pessimism, other FUD, 6 times statement, etc. By the way Dew, I am short MNTA and yes the position is down but my fund is up well into double digits this year so before you get concerned, don't.
More importantly, regarding JP's "slam dunk" comment. After having known JP for 5 years I believe the comment stems more from his frustration with the market's perception of the company's prospects (as evidenced by the current market cap, the endless speculation of p values with 7 or so zeros, funds owning the stock who keep blowing up and have to exit) rather than pumping or naivety or whatever. This is his midwestern straightforward way of communicating to the market that he has conviction. After having spent all of my life either in the midwest and NY/NE, I understand JP and I understand the East Coast's reaction to him. The reaction of an East Coaster to a midwesterner is always bipolar- either they are charmed or they hate the no-nonsense straightforwardness of the person. In JPs case, a vast majority of East Coast funds that I have spoken to have traditionally had the latter opinion but I am hopeful with the continued delivery of results from the company that he will win more and more of them over.
JP is a straight shooter and when there is doubt he gravitates toward more disclosure/conviction/whatever and those that view him as too straightforward or even promotional view the additional statements as even more so.
Personally, I prefer straightforward in management. I think too many people have been burned more by the nebulous management teams- remember ENCY, etc.
Recent RPRX News
- Royalty Pharma Announces Inaugural Prize for Impact in Healthcare • GlobeNewswire Inc. • 11/14/2024 09:30:00 PM
- Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million • GlobeNewswire Inc. • 11/07/2024 12:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2024 02:24:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 12:35:00 PM
- Royalty Pharma Reports Third Quarter 2024 Results • GlobeNewswire Inc. • 11/06/2024 12:15:00 PM
- Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo • GlobeNewswire Inc. • 11/04/2024 09:15:00 PM
- Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ • PR Newswire (US) • 11/04/2024 09:01:00 PM
- Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024 • GlobeNewswire Inc. • 10/16/2024 08:15:00 PM
- Royalty Pharma Declares Fourth Quarter 2024 Dividend • GlobeNewswire Inc. • 10/11/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 12:39:00 PM
- Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement • GlobeNewswire Inc. • 09/03/2024 09:14:32 PM
- Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement • GlobeNewswire Inc. • 09/03/2024 09:06:29 PM
- Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference • GlobeNewswire Inc. • 08/28/2024 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:20:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:19:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 01:02:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:20:53 AM
- Royalty Pharma Reports Second Quarter 2024 Results • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:04:01 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/29/2024 08:30:11 PM
- Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital • GlobeNewswire Inc. • 07/24/2024 12:30:00 PM
- Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 • GlobeNewswire Inc. • 07/19/2024 12:15:00 PM
- Royalty Pharma Declares Third Quarter 2024 Dividend • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:03:31 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM